Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Reports $29M in Preliminary 2013 Revenue

NEW YORK (GenomeWeb News) – Foundation Medicine today reported unaudited total revenue of $29 million for the year ended Dec. 31, 2013, compared to less than $11 million for 2012.

The company's preliminary revenues beat consensus analyst estimates for the year of $28 million.

Oncologists ordered around 3,750 FoundationOne clinical tests in the fourth quarter, compared to 2,577 for the year-ago quarter. For the whole year, oncologists ordered 9,000 tests.

Foundation Medicine CEO Michael Pellini attributed strong fourth-quarter adoption of FoundationOne to the firm's growing commercial team and to greater repeat testing among oncologists in the academic and community settings.

Foundation Medicine's lead product, FoundationOne, is a targeted next-generation sequencing test that gauges more than 200 cancer-related genes. Foundation One in 2013 launched its second clinical product, FoundationOne Heme, for patients with hematologic malignancies and sarcomas, and opened a new lab facility that allowed it to expand its operational capabilities.

Foundation Medicine said it will launch an updated version of FoundationOne with an expanded panel of genes related to solid tumors in the first half of this year. It also plans to introduce new features for its Interactive Cancer Explorer physician portal in the second half of the year.

The company said it expects to deliver between 22,000 and 25,000 tests in 2014, driven by FoundationOne and FoundationOne Heme.

The company projected 2014 revenues to be between $52 million and $58 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more